000053143 001__ 53143
000053143 005__ 20180211174126.0
000053143 0247_ $$2pmid$$apmid:16845512
000053143 0247_ $$2DOI$$a10.1007/s00259-006-0176-5
000053143 0247_ $$2WOS$$aWOS:000241522600002
000053143 0247_ $$2ISSN$$a1432-105X
000053143 037__ $$aPreJuSER-53143
000053143 041__ $$aeng
000053143 082__ $$a610
000053143 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000053143 1001_ $$0P:(DE-Juel1)VDB612$$aHerzog, H.$$b0$$uFZJ
000053143 245__ $$aAssessment of the short-lived non-pure positron-emitting nuclide 120I for PET imaging
000053143 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2006
000053143 300__ $$a1249 - 1257
000053143 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000053143 3367_ $$2DataCite$$aOutput Types/Journal article
000053143 3367_ $$00$$2EndNote$$aJournal Article
000053143 3367_ $$2BibTeX$$aARTICLE
000053143 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000053143 3367_ $$2DRIVER$$aarticle
000053143 440_0 $$09906$$aEuropean Journal of Nuclear Medicine and Molecular Imaging$$v33$$x1619-7070$$y11
000053143 500__ $$aRecord converted from VDB: 12.11.2012
000053143 520__ $$aThe non-pure positron-emitting iodine isotope (120)I (T(1/2)=81 min) is a short-lived alternative to (124)I. (120)I has a positron abundance more than twice that of (124)I and a maximum positron energy of 4 MeV. This study was undertaken to evaluate and characterise the qualitative and quantitative PET imaging of (120)I.(120)I was produced via the (120)Te(p,n) reaction on highly enriched (120)Te. The measurements were done with the Siemens scanner HR+ and the 2D PET scanner GE PC4096+. A cylinder containing three cold inserts and a phantom resembling a human brain slice were used to evaluate half-life, positron abundance and background correction. To analyse the image resolution, a -mm tube placed in water was filled with (120)I and (18)F. Comparisons with (18)F, (124)I and (123)I (measured with SPECT) were made using the Hoffman 3D brain phantom.The half-life of 81.1 min was reproduced by the PET measurements. The PET-based positron abundance ranged from 47.9% to 55.0%. The reconstructed image resolution found with the HR+ was 5.4 mm FWHM (12.3 mm FWTM), in contrast to 4.6 mm (8.6 mm) when using (18)F. Erroneous positive and negative numbers of radioactivity found in the cold inserts became nearly zero when the background of gamma-coincidences was corrected for. Images of the Hoffman phantom were inferior to those obtained when (18)F or (124)I was applied but superior to the (123)I-SPECT images.Our data show that (120)I of high radionuclidic purity can be regarded as a suitable nuclide for the PET imaging of radioiodine-labelled pharmaceuticals.
000053143 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000053143 588__ $$aDataset connected to Web of Science, Pubmed
000053143 650_2 $$2MeSH$$aBrain: radionuclide imaging
000053143 650_2 $$2MeSH$$aHumans
000053143 650_2 $$2MeSH$$aImage Enhancement: methods
000053143 650_2 $$2MeSH$$aImage Interpretation, Computer-Assisted: methods
000053143 650_2 $$2MeSH$$aIodine Radioisotopes: chemistry
000053143 650_2 $$2MeSH$$aIodine Radioisotopes: diagnostic use
000053143 650_2 $$2MeSH$$aIsotope Labeling: methods
000053143 650_2 $$2MeSH$$aPhantoms, Imaging
000053143 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000053143 650_2 $$2MeSH$$aRadiopharmaceuticals: chemical synthesis
000053143 650_2 $$2MeSH$$aRadiopharmaceuticals: diagnostic use
000053143 650_2 $$2MeSH$$aReproducibility of Results
000053143 650_2 $$2MeSH$$aSensitivity and Specificity
000053143 650_7 $$00$$2NLM Chemicals$$aIodine Radioisotopes
000053143 650_7 $$00$$2NLM Chemicals$$aRadiopharmaceuticals
000053143 650_7 $$2WoSType$$aJ
000053143 65320 $$2Author$$aiodine
000053143 65320 $$2Author$$aPET
000053143 65320 $$2Author$$areconstruction quantification
000053143 7001_ $$0P:(DE-Juel1)VDB1300$$aQaim, S. M.$$b1$$uFZJ
000053143 7001_ $$0P:(DE-Juel1)131797$$aTellmann, L.$$b2$$uFZJ
000053143 7001_ $$0P:(DE-Juel1)VDB1552$$aSpellerberg, S.$$b3$$uFZJ
000053143 7001_ $$0P:(DE-HGF)0$$aKruecker, D.$$b4
000053143 7001_ $$0P:(DE-Juel1)131816$$aCoenen, H. H.$$b5$$uFZJ
000053143 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-006-0176-5$$gVol. 33, p. 1249 - 1257$$p1249 - 1257$$q33<1249 - 1257$$tEuropean Journal of Nuclear Medicine and Molecular Imaging$$v33$$x1619-7070$$y2006
000053143 8567_ $$uhttp://dx.doi.org/10.1007/s00259-006-0176-5
000053143 909CO $$ooai:juser.fz-juelich.de:53143$$pVDB
000053143 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000053143 9141_ $$y2006
000053143 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000053143 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000053143 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000053143 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000053143 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000053143 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000053143 9201_ $$0I:(DE-Juel1)VDB54$$d31.12.2006$$gIME$$kIME$$lInstitut für Medizin$$x0
000053143 9201_ $$0I:(DE-Juel1)VDB53$$d31.12.2006$$gINC$$kINC$$lInstitut für Nuklearchemie$$x1
000053143 970__ $$aVDB:(DE-Juel1)83582
000053143 980__ $$aVDB
000053143 980__ $$aConvertedRecord
000053143 980__ $$ajournal
000053143 980__ $$aI:(DE-Juel1)INB-3-20090406
000053143 980__ $$aI:(DE-Juel1)INM-5-20090406
000053143 980__ $$aUNRESTRICTED
000053143 981__ $$aI:(DE-Juel1)INB-3-20090406
000053143 981__ $$aI:(DE-Juel1)INM-5-20090406